K-645
/ Kallyope
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 16, 2025
A First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-645 in Healthy Volunteers
(ANZCTR)
- P1 | N=16 | Completed | Sponsor: Kallyope, Inc. | Recruiting ➔ Completed
Trial completion • CNS Disorders • Migraine • Pain
1 to 1
Of
1
Go to page
1